What did @awakenwithlexy actually say?
After just two doses of a peptide product she calls a "glow peptide" containing BPC-157 and copper (almost certainly GHK-Cu), the creator reports feeling "good in my body," noticing pressure in her carpal tunnels and knee that she interprets as active tissue repair, experiencing a "stable baseline of energy," waking at 1:30 a.m. feeling rested, and seeing visible skin glow. She also mentions persistent thirst despite the product claiming to hydrate "at a cellular level." She's planning to stack additional peptides and has adjusted her reconstitution volume to reduce injection sting.
To her credit, she hedges repeatedly. She says "maybe I'm just having a really good makeup day" about her skin and acknowledges she won't know if her knee is improving until she stresses it. That kind of self-awareness is genuinely rare in this category of content.
Does the science back this up?
For BPC-157, there's real preclinical signal, but the human data is thin. Most of the excitement comes from animal studies, and that gap matters.
BPC-157 (Body Protection Compound-157) has shown consistent results in rodent models for tendon repair, gut healing, and nerve recovery. A 2018 review by Sikiric et al. in Current Pharmaceutical Design summarized decades of animal research suggesting BPC-157 promotes angiogenesis and collagen synthesis at injury sites. The proposed mechanism involves upregulation of growth factor receptors, particularly VEGFR2. That's a plausible biological reason why someone with old carpal tunnel damage or a knee injury might feel localized sensation.
GHK-Cu (copper peptide) has stronger skin-relevant data. A 2015 paper by Pickart and Margolina in Biomolecules documented its role in stimulating collagen synthesis and activating antioxidant enzymes in human fibroblast studies. Two doses producing visible glow? Unlikely from a pharmacological standpoint. But the mechanism to eventually produce that outcome exists.
The "cellular hydration" claim from the product itself has no meaningful peer-reviewed support as a defined mechanism.
What did they get wrong (or right)?
The repair-pressure sensation is the most interesting part of this video, and it's also the most speculative. She says she felt "pressure" in her knee and carpal tunnels the first night, then nothing the next morning, and concludes it might be the peptide repairing tissue. This interpretation is a stretch.
Localized sensation after a systemic subcutaneous injection could be placebo response, coincidental inflammation cycling, or simply heightened attention to body signals after taking something new. BPC-157 does appear to modulate nitric oxide pathways, which could theoretically affect local circulation, but "feeling repair happen" overnight after dose one is not a documented phenomenon in any study population.
What she got right: her instinct to stress-test the knee before declaring results is actually the correct scientific approach. The energy description, "not like a coffee hit, more like a stable baseline," is consistent with anecdotal patterns reported in observational contexts, though no controlled trial has measured this in humans. Her caution about stacking before resolving the thirst issue is reasonable harm-reduction thinking.
The thirst she's experiencing is worth taking seriously. BPC-157 is not known to cause dehydration, but injection site reactions and systemic peptide responses can vary. She should flag this with whoever is supervising her use.
What should you actually know?
BPC-157 is not FDA-approved for human use. It exists in a gray-market space where it's often sold as a research chemical or compounded through specialized pharmacies operating under evolving regulatory frameworks. In 2022, the FDA moved to restrict compounding of BPC-157, citing insufficient evidence of safety and efficacy in humans. That regulatory status hasn't stopped widespread use, but it's context you deserve before watching two doses become a wellness routine on TikTok.
GHK-Cu has a comparatively cleaner regulatory profile as a cosmetic ingredient, and the skin science behind copper peptides is more established than most peptide marketing admits.
- No human clinical trial has confirmed BPC-157 repairs tendons or joints in people.
- Reconstitution math and dilution adjustments, as she describes, affect actual dose delivered. This is a real variable, not a minor detail.
- Stacking peptides without clinical supervision increases the complexity of attributing effects or side effects to any single compound.
- Persistent thirst after starting a new injectable compound should be reported to a prescribing clinician, not solved with electrolytes alone.